title: Treatment and prognosis in sinonasal mucosal melanoma: A retrospective analysis of 65 patients from a single cancer center.
abstract: BACKGROUND
  The purpose of this study was to evaluate the outcome in sinonasal mucosal melanoma (SMM).
  
  
  METHODS
  A retrospective analysis of clinicopathological data from January 1976 to December 2005 was performed. Survival curve, univariate, and multivariate analyses were undertaken.
  
  
  RESULTS
  Sixty-eight patients with SMM were enrolled; 3 patients refused treatment. The 3-year and 5-year overall survival (OS) rates in the remaining 65 cases of SMM were 36.5% and 29.7%, respectively. Patients who underwent surgery had better 3-year and 5-year OS rates than those treated without surgery (40.7% and 34.1% vs 21.4% and 14.3%, respectively), and the same was true for patients treated with and without biotherapy (58.2% and 50.9% vs 30.0% and 23.4%, respectively). Distant metastasis at presentation was associated with a worse prognosis. Those patients managed with multimodality treatment had better OS rates.
  
  
  CONCLUSIONS
  The prognosis in SMM is poor, particularly for those with distant metastasis or without surgery. Multimodality treatment may improve survival.
authors.affiliation: Department of Head and Neck Surgery, The Third Affiliated Hospital of Kunming Medical University, Kunming, People's Republic of China.
authors.forename: Chuan-Zheng
authors.initials: CZ
authors.lastname: Sun
authors.forename: Qiu-Li
authors.initials: QL
authors.lastname: Li
authors.forename: Ze-Dong
authors.initials: ZD
authors.lastname: Hu
authors.forename: Yu-E
authors.initials: YE
authors.lastname: Jiang
authors.forename: Ming
authors.initials: M
authors.lastname: Song
authors.forename: An-Kui
authors.initials: AK
authors.lastname: Yang
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001500:BCG Vaccine / Q000627:therapeutic use; D002173:Cancer Care Facilities; D016009:Chi-Square Distribution; D002648:Child; D002675:Child, Preschool; D015331:Cohort Studies; D003131:Combined Modality Therapy; D016001:Confidence Intervals; D018572:Disease-Free Survival; D019583:Dose Fractionation, Radiation; D005260:Female; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D015850:Interleukin-6 / Q000627:therapeutic use; D008297:Male; D008545:Melanoma / Q000401:mortality* / Q000473:pathology / Q000628:therapy*; D008875:Middle Aged; D015999:Multivariate Analysis; D009297:Nasal Mucosa / Q000473:pathology*; D059747:Nasal Surgical Procedures / Q000379:methods / Q000401:mortality; D009361:Neoplasm Invasiveness / Q000473:pathology; D009367:Neoplasm Staging; D010255:Paranasal Sinus Neoplasms / Q000401:mortality* / Q000473:pathology / Q000628:therapy*; D016016:Proportional Hazards Models; D018714:Radiotherapy, Adjuvant; D011994:Recombinant Proteins / Q000627:therapeutic use; D012189:Retrospective Studies; D018570:Risk Assessment; D015996:Survival Rate; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D001500:BCG Vaccine; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D015850:Interleukin-6; D011994:Recombinant Proteins
keywords: biotherapy; mucosal melanoma; prognosis; sinonasal; treatment